Kintara Therapeutics Inc
General ticker "KTRA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $4.6M
Kintara Therapeutics Inc does not follow the US Stock Market performance with the rate: -21.8%.
Estimated limits based on current volatility of 9.0%: low 6.80$, high 8.14$
Factors to consider:
- Earnings for 12 months up through Q4 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-06-30 to 2025-06-29
- 2023-06-30 to 2024-06-29 estimated range: [41.77$, 156.58$]
- 2024-06-29 to 2025-06-29 estimated range: [26.10$, 91.04$]
Financial Metrics affecting the KTRA estimates:
- Negative: Operating Income to Revenue ratio of -0.99 <= 0.01
- Negative: Non-GAAP EPS of -9.49 <= 0.11
- Negative: negative Net Income
- Negative: Operating Cash Flow per share of -7.32 <= 0.22
- Negative: Industry Operating Cash Flow per share (median) of -1.58 <= 0.31
Short-term KTRA quotes
Long-term KTRA plot with estimates
Financial data
| YTD | 2021-06-30 | 2022-06-30 | 2023-06-30 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.15MM |
| Operating Expenses | $21.67MM | $22.69MM | $14.80MM |
| Operating Income | $-21.67MM | $-22.69MM | $-14.65MM |
| Non-Operating Income | $-16.76MM | $0.03MM | $0.00MM |
| Interest Expense | $0.03MM | $0.00MM | $0.00MM |
| R&D Expense | $11.81MM | $15.17MM | $9.31MM |
| Income(Loss) | $-38.43MM | $-22.66MM | $-14.65MM |
| Profit(Loss) | $-38.43MM | $-22.66MM | $-14.65MM |
| Stockholders Equity | $10.58MM | $11.79MM | $0.73MM |
| Assets | $13.54MM | $15.95MM | $3.98MM |
| Operating Cash Flow | $-18.86MM | $-20.39MM | $-11.87MM |
| Investing Cash Flow | $0.96MM | $0.00MM | $-0.23MM |
| Financing Cash Flow | $26.04MM | $21.64MM | $1.85MM |
| Earnings Per Share* | $-74.02 | $-23.22 | $-9.04 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.